Azitra, Inc. (AZTR) AI Stock Analysis
AZTR AI stock analysis summary
AI ResearchAzitra, Inc. (AZTR) is an early-stage biopharmaceutical company focused on precision dermatology therapies. Over the trailing twelve months, the company generated $0 in revenue with an EPS of -$0.28. Its balance sheet as of June 30, 2026, held $6.7M in cash and short-term investments alongside a net cash position of $6.3M.
- Market cap
- $4.3M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -89.8% S&P 500 16.8%
- Avg. target
- $0.67 830.6% vs last close
Bull case
- The company holds a net cash position of $6.3M with minimal total debt of $410,053 as of June 30, 2026.
- Analysts maintain a mean price target of $0.67, representing 830.6% upside from the last close of $0.07.
- Consensus estimates project EPS to improve by 91.1% in the current fiscal year to -$0.20.
Bear case
- Trailing twelve-month revenue fell to $0 following a 100.0% year-over-year revenue drop in the quarter ended June 30, 2026.
- AZTR generated negative free cash flow of -$10.6M in FY2024 while posting a net loss of -$9.0M.
- The stock declined 89.8% over the trailing one-year period and trades 62.7% below its 200-day average.
What Azitra does
Headquartered in Branford, Connecticut, Azitra, Inc. develops therapies in precision dermatology using engineered proteins and live biotherapeutic products. Its primary clinical candidate is ATR-12, a genetically modified strain of S. epidermidis currently in Phase Ib clinical trials for Netherton syndrome, a rare genetic skin disorder causing chronic inflammation and defective skin barrier function. The company is also advancing ATR-04, another engineered S. epidermidis candidate designed to reduce papulopustular rashes in cancer patients treated with EGFR inhibitors, as well as ATR-01, an engineered recombinant human filaggrin protein targeting ichthyosis vulgaris.
Growth and profitability
Azitra reported revenue of $110,000 in FY2021, $284,000 in FY2022, and $686,000 in FY2023, before declining 98.9% to $7,500 in FY2024. Over the 3-year period from FY2021 to FY2024, revenue compound annual growth rate was -59.1%. Gross margin was 100.0% across all four fiscal years, while operating margin was -146468.5% in FY2024. Net income remained negative, moving from -$8.9M in FY2021 to -$10.7M in FY2022, -$11.3M in FY2023, and -$9.0M in FY2024. In the latest quarter ended June 30, 2026, quarterly revenue growth fell 100.0% year-over-year, leading to trailing twelve-month revenue of $0 and EPS of -$0.28.
Balance sheet and cash flow
As of June 30, 2026, Azitra reported $6.7M in cash and short-term investments, total debt of $410,053, and a net cash balance of $6.3M. Total assets stood at $8.9M against shareholders' equity of $7.3M. The company showed a current ratio of 4.86 and a debt-to-equity ratio of 0.06. In FY2024, free cash flow was -$10.6M with operating cash flow of -$10.2M. Capital expenditures were $186,062 in FY2025.
Valuation and performance
At a last close of $0.07 on October 16, 2026, Azitra carried a market cap of $4.3M and an enterprise value of $3.7M. The stock traded at a price-to-sales multiple of 240.0x and an EV-to-revenue multiple of 220.1x, well above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio stood at 1.4x. Over the past year, AZTR shares fell 89.8%, trailing the S&P 500 return of 16.8%. The stock traded 62.7% below its 200-day average.
What analysts expect
Wall Street coverage includes 1 Buy rating and 0 Hold or Sell ratings. The mean price target is $0.67, representing an 830.6% premium over the last close of $0.07. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$0.20. For the following fiscal year, 2 analysts estimate revenue of $0 and EPS of -$0.10. Over the last 4 quarters, the company delivered 2 EPS beats. The next earnings date is November 11, 2026.
Key risks and what to watch
- With revenue at $0 for the trailing twelve months, commercial viability relies entirely on early-stage pipeline candidates.
- Ongoing operating cash burn, which reached -$10.2M in FY2024, poses liquidity risks against $6.7M in cash and short-term investments.
- A 3-year revenue CAGR of -59.1% demonstrates severe top-line contraction from FY2021 to FY2024.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AZTR AI stock analysis
This page is an AI-written research summary of Azitra, Inc. (AZTR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AZTR income statement, AZTR balance sheet, AZTR key metrics, AZTR analyst forecast, AZTR chart. See the AZTR stock overview for the latest quote and news.
AZTR AI stock analysis FAQ
Does Azitra pay a dividend?
No, Azitra does not pay a dividend.
What is Azitra's cash position?
As of June 30, 2026, Azitra held $6.7M in cash and short-term investments alongside total debt of $410,053, providing net cash of $6.3M. Its current ratio was 4.86.
What products are in Azitra's clinical pipeline?
Azitra's primary candidate is ATR-12, currently in Phase Ib clinical trials for Netherton syndrome. The company is also developing ATR-04 for cancer therapy-induced rashes and ATR-01 for ichthyosis vulgaris.
What is the analyst price target for AZTR?
The mean analyst price target is $0.67, which is 830.6% above the last close price of $0.07. One analyst currently covers the stock with a Buy rating.